Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

To the Editor: According to Leidner et al. (June 2 issue),(1) anti-KRAS G12D T-cell treatment produced a partial response in a patient with pancreatic ductal adenocarcinoma and metachronous lung metastases. We bring up two points that may aid in understanding the underlying reasons and guide patient selection. First, patients with pancreatic ductal adenocarcinoma who have the lung as the sole site of metastasis form a distinct subgroup of patients with favorable clinical outcomes, which is hypothesized to be aided by immunity.(2) Second, the T cells used had a tissue-resident phenotype with high CD103 expression, which is known to correlate tightly . . .

Automated summary

This letter discusses a study on the treatment of pancreatic ductal adenocarcinoma with lung metastases using anti-KRAS G12D T-cell therapy. Two points are brought up: firstly, patients with lung-only metastases from pancreatic ductal adenocarcinoma have favorable clinical outcomes, possibly due to immunity; secondly, the T cells used in the study had a tissue-resident phenotype with high CD103 expression, which is closely correlated to the treatment response.